Prediagnostic Serum 25-Hydroxyvitamin D and Mortality Among Bladder Cancer Patients in the Janus Serum Bank Cohort: A Short Comment [Letter]

Reza Rastmanesh^{1,2}

¹The Nutrition Society, London, UK;

²The American Physical Society, College Park, MD, USA

Dear editor

I read with interest the article by Hektoen et al.¹ The authors have concluded that: 1) 25 (OH)D deficiency prior to a bladder cancer (BC) diagnosis is associated with increased risk of BC-specific mortality, when compared to insufficient levels; and 2) results were pronounced among non-muscle invasive BC (NMIBC) patients only, suggesting a more critical role of vitamin D deficiency in an early stage of the disease. While their results can be partly true, their interpretation and conclusion suggesting a more critical role of vitamin D deficiency in an early stage of the disease is subject to many biases and meanwhile can be clinically/epidemiologically misleading.

Firstly, vitamin D status is a function of many factors, including the 7-dehydrocholesterol concentration in epidermis (which in turn is a function of dietary cholesterol intake and serum cholesterol concentration), and melanin pigmentation, skin melanin pigmentation, sunscreen use, clothing, season, time of day, aging and latitude.² To become active, vitamin D underwent two hydroxylation steps in the liver and kidneys, as the authors acknowledge. This simply means that sufficient/proper/functional hydroxylation is critically associated with the expression and serum levels of 1-alpha hydroxylases and 25-alpha hydroxylases² in functional/healthy liver and kidneys, respectively.

Indeed, multiple deregulated metabolic changes result in bladder cancer,^{3–5} namely impaired hepatic cytochrome P450 oxidoreductase,⁵ dysregulation of MMP-1 expression in response to hypoxia, which in turn is dependent on the intracellular redox status of metastatic bladder cancer cells,⁴ and altered cellular metabolism, drastic changes in glycolysis and mitochondrial metabolism,³ just to mention a few.

This means that insufficient vitamin D status—besides insufficient dietary vitamin D intake—is indicative of multiple cellular abnormalities within the hepatic and renal cells, directly leading to BC, not vitamin D status per se de facto.

Secondly, their cohort study is carried out in Norway, with a wide latitude and, it is not indicated in which season the blood samples are taken.

Thirdly, they suggest a more critical role of vitamin D deficiency in an early stage of the disease, like many other authors. Extreme caution should be taken here, as many readers may interpret this as an encouraging note to focus correction of serum vitamin D levels, instead of individualized clinical evaluation strategy and practice guidelines.

Correspondence: Reza Rastmanesh
#6, Physicians Building, Sarshar Alley, Vali
Asr Street, Tajrish, Tehran, 1961835555,
Iran
Email r.rastmanesh@gmail.com

These imply that their conclusion emphasizing that a more critical role of vitamin D deficiency in an early stage of the disease could be either an artifact, or association in some patients might be more pronounced (ie, in participants who had renal or hepatic disease or both), while in some samples, associations might be attenuated (ie, in patients who had not renal/hepatic diseases). Authors might choose to re-analyze their data, particularly if they could adjust for confounding factors such as data on renal and hepatic diseases (and other confounders), in case data were available. A mediation analysis performed to support the conclusion is also recommended.

Disclosure

The author reports no competing or conflicts of interest for this communication.

References

1. Hektoen HH, Gislefoss RE, Stenehjem JS, et al. Prediagnostic serum 25-Hydroxyvitamin D and mortality among bladder cancer patients in the Janus Serum Bank Cohort. *Clin Epidemiol.* **2021**;13:801–813. doi:10.2147/CLEP.S319620
2. Chen TC, Lu Z, Holick MF. *Photobiology of Vitamin D*. Springer; **2010**:35–60.
3. Woolbright BL, Ayres M, Taylor JA III. *Metabolic Changes in Bladder Cancer*. Elsevier; **2018**:327–337.
4. Shin DH, Dier U, Melendez JA, et al. Regulation of MMP-1 expression in response to hypoxia is dependent on the intracellular redox status of metastatic bladder cancer cells. *Biochim Biophys Acta Mol Basis Dis.* **2015**;1852(12):2593–2602. doi:10.1016/j.bbdis.2015.09.001
5. Xiao X, Ma G, Li S, et al. Functional POR A503V is associated with the risk of bladder cancer in a Chinese population. *Sci Rep.* **2015**;5(1):1–11. doi:10.1038/srep11751

Dove Medical Press encourages responsible, free and frank academic debate. The content of the Clinical Epidemiology 'letters to the editor' section does not necessarily represent the views of Dove Medical Press, its officers, agents, employees, related entities or the Clinical Epidemiology editors. While all reasonable steps have been taken to confirm the content of each letter, Dove Medical Press accepts no liability in respect of the content of any letter, nor is it responsible for the content and accuracy of any letter to the editor.

Clinical Epidemiology

Dovepress

Publish your work in this journal

Clinical Epidemiology is an international, peer-reviewed, open access, online journal focusing on disease and drug epidemiology, identification of risk factors and screening procedures to develop optimal preventative initiatives and programs. Specific topics include: diagnosis, prognosis, treatment, screening, prevention, risk factor modification,

systematic reviews, risk & safety of medical interventions, epidemiology & biostatistical methods, and evaluation of guidelines, translational medicine, health policies & economic evaluations. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use.

Submit your manuscript here: <https://www.dovepress.com/clinical-epidemiology-journal>

<https://doi.org/10.2147/CLEP.S339834>